Researchers in the Gynecologic Oncology Program are exploring gynecologic cancers from a wide variety of scientific angles – from discoveries about the genes that cause tumors to develop and grow, to investigations of immunotherapies, to studies of ways
drugs can be combined to fight recurrent cancer.
Our basic scientists are looking at immune response through laboratory studies, creating laboratory models to study cancer resistance, and researching how to
exploit DNA repair defects. They are also exploring the genetic underpinnings of gynecologic cancers to find the mutations responsible for the disease. Our physician-scientists are focused on the development of new treatments for specific subtypes
of gynecologic cancers, including PARP inhibitors for BRCA-related high grade serous ovarian cancer, as well as methods for early detection of ovarian cancer.
Clinical Trials
We base our treatments on the latest scientific findings, and offer our patients the opportunity to participate in clinical trials of promising new treatments. Our clinical trial program is one of the largest and most active in the country, with more
than 20 open studies.
Many patients with gynecologic cancer – particularly ovarian – are diagnosed at a later stage when there are fewer conventional therapies. Many of our clinical trials offer new options for these patients, as we test new drugs as single agents or in combinations.
We pioneered many new treatments for gynecologic cancer (particularly ovarian) such as DNA repair treatments (including PARP inhibitors), immunotherapy, antibody drug conjugates, and anti-angiogenesis agents. Our leaders were involved in the research
leading to recent FDA approval of PARP inhibitors for recurrent ovarian cancer. We also have active trials studying strategies to overcome drug resistance, particularly to the platinum drugs often used in ovarian, endometrial, and cervical cancers.
Featured Clinical Trials
Ovarian Cancer Clinical Trials
Trial 20-096: SORAYA - A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Principal investigator: Ursula A. Matulonis, MD
Trial 18-227: A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer
Principal investigator: Joyce F. Liu, MD, MPH
Trial 19-408: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Principal investigator: Panagiotis (Panos) A. Konstantinopoulos, MD, PhD
Find other trials for ovarian cancer
Endometrial Cancer Clinical Trials
Trial 18-316: A Phase 2 Study of the Wee1 inhibitor AZD1775 in women with recurrent or persistent uterine serous carcinoma
Principal investigator: Joyce F. Liu, MD, MPH
Trial 18-602: A Phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC)
Principal investigator: Jennifer L. Veneris, MD, PhD
Trial 16-322: A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients with MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab (MSB0010718C) / Talazoparib (MDV3800, BMN 673) in Patients with MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in patients with MSS Recurrent or Persistent Endometrial Cancer
Principal investigator: Panagiotis (Panos) A. Konstantinopoulos, MD, PhD
Find other trials for endometrial cancer
Cervical Cancer Clinical Trials
Trial 19-092: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TFADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
Principal investigator: Susana M. Campos, MD, MPH
Find other trials for cervical cancer
Search all Dana-Farber clinical trials